Socioeconomic status and prescribing for schizophrenia: Analysis of 3200 cases from the Glasgow Psychosis Clinical Information System (PsyCIS)

BJPsych Bulletin

Volumn 38, Issue 2, 2014, Pages 54-57

  Martin, Daniel J ^a   Park, John ^b   Langan, Julie ^a   Connolly, Moira ^b   Smith, Daniel J ^a   Taylor, Mark ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^c ROYAL EDINBURGH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; PSYCHOTROPIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLASGOW PSYCHOSIS CLINICAL INFORMATION SYSTEM; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION SYSTEM; OUTCOME ASSESSMENT; POLYPHARMACY; PRESCRIPTION; PSYCHOPHARMACOTHERAPY; SCHIZOPHRENIA; SOCIAL STATUS; ASSESSMENT OF HUMANS; MENTAL HEALTH SERVICE; SCOTTISH INDEX OF MULTIPLE DEPRIVATION; TREATMENT-RESISTANT SCHIZOPHRENIA;

EID: 84973474063     PISSN: 20564694     EISSN: 20564708     Source Type: Journal    
DOI: 10.1192/pb.bp.112.042143     Document Type: Article

References (11)

1. Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, et al. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry 2000; 34: 221-36.
2. Wheeler A. Sociodemographic, functional and clinical correlates in outpatients with schizophrenia: comparison with affective disorders. Aust N Z J Psychiatry 2007; 41: 809-18.
3. Franz M, Ranger J, Hanewald B, Gallhofer B, Lay B. Influences on therapist's decisions for neuroleptic treatment in schizophrenia: the role of characteristics of the patient and the physician. Pharmacopsychiatry 2012; 45: 261-8.
4. The Scottish Government. The Scottish Index of Multiple Deprivation: 2009 General Report. The Scottish Government, 2009.
5. Park J, McAlaney C, Connolly M. Improving patient care and clinical governance through the utilisation of a clinical information system. Clin Governance 2008; 13: 254-9.
6. Waterreus A, Morgan VA, Castle D, Galletly C, Jablensky A, Di Prinzio P, et al. Medication for psychosis - consumption and consequences: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012; 46: 762-73.
7. Langan J, Shajahan P. Antipsychotic polypharmacy: review of mechanisms, mortality and management. Psychiatrist 2010; 34: 58-62.
8. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999; 53 (Suppl): S35-40.
9. National Institute for Health and Clinical Excellence. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. NICE Clinical Guideline CG82. NICE.
10. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010; 67: 26-36.
11. Taylor D, Mace S, Kerwin R. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Practice 2000; 4: 41-6.